Anaptysbio vs Ideaya Biosciences
Anaptysbio and Ideaya Biosciences are similar in size: $235m and $219m of revenue in their latest fiscal years. Ideaya Biosciences grew faster (3024.4% against 157.0%). Anaptysbio kept more of each dollar of sales as profit: a net margin of -5.6% against -52.0%. Anaptysbio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AnaptysbioANAB, 2025 | Ideaya BiosciencesIDYA, 2025 |
|---|---|---|
| Revenue | $235m | $219m |
| Revenue growth | 157.0% | 3024.4% |
| Net income | −$13.2m | −$114m |
| Operating margin | 96.7% | -72.8% |
| Net margin | -5.6% | -52.0% |
| Return on equity | -24.5% | -10.9% |
| Free cash flow | $19.6m | −$73.5m |
| Cash | $138m | $113m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $68.6m | — |
| Employees | 104 | 145 |
| Market value | $1.42bn | $3.02bn |
| Price vs our value range | — | — |
| Moat score | 13 (Weak) | — |
| Insider trades, 12 months | 0 buys, 42 sales | 1 buys, 3 sales |